Author: @admin

Post

ContraFect to Present at the Bacteriophage Therapy Summit

YONKERS, N.Y., March 21, 2019 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development will participate in the inaugural Bacteriophage Therapy...

Post

Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company’s request for a Type A meeting to discuss the points raised in the Complete Response Letter received from the FDA related to the New Drug Application (NDA)...

Post

Paratek Pharmaceuticals Announces Management Change

BOSTON, March 18, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that Douglas Pagán, Chief Financial Officer, has resigned, effective April 5, 2019, to join an early-stage biopharmaceutical company. Mr. Pagán has entered into a consulting agreement with Paratek...

Post

Summit Therapeutics to Present at Upcoming Conferences

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at Upcoming Conferences Oxford, UK, and Cambridge, MA, US, 18 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that management will present at two upcoming conferences. Details of the conference presentations: Superbugs & Superdrugs...

Post

Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard C. E. Morgan has tendered his resignation as Non-executive Chairman and is stepping down from the Board of Directors, effective immediately, to focus on other business commitments. Bruce Williams,...

Post

SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update

JERSEY CITY, N.J., March 14, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the year ended December 31, 2018, and provided an update on recent operational and clinical developments. “We ended 2018 having accomplished meaningful progress across our ibrexafungerp clinical...

Post

Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference

Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference N. Gonorrhoeae and ESKAPE Pathogens Identified as High Priority by the US CDC and the WHO Oxford, UK, and Cambridge, MA, US, 14...

Post

ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

YONKERS, N.Y., March 14, 2019 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced financial results for the fourth quarter and full year ended December 31, 2018. “2018 was a milestone year for ContraFect. We completed...

Post

Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results

~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from Prior Quarter ~ ~ Corporate Milestones Across Commercial Operations, Clinical and Business Development Provide Critical Growth Opportunities ~ ~ Provides...

Post

ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference

YONKERS, New York, March 13, 2019 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company’s Chairman and Chief Executive Officer, will participate in the 29th Annual Oppenheimer Healthcare Conference...